Thermo Fisher Scientific (TMO) Receivables - Net (2009 - 2026)

Thermo Fisher Scientific has reported Receivables - Net for 18 years, with the latest figure at $9.5 billion in Q2 2026.

• Receivables - Net for Q2 2026 came in at $9.5 billion, up 9.97% year-over-year; the trailing twelve-month figure through Jun 2026 was $9.5 billion (up 9.97% YoY), and the FY2025 annual result was $8.9 billion, up 8.66% from the prior year.
• Receivables - Net improved to $9.5 billion in Q2 2026, from $9.2 billion in the prior quarter.
• Over five years, Receivables - Net peaked at $9.5 billion in Q2 2026 and troughed at $7.7 billion in Q4 2022.
• A 5-year average of $8.3 billion and a median of $8.2 billion in 2023 frame the typical range for Receivables - Net.
• The widest annual swing landed in 2022, when Receivables - Net jumped 42.04%; it then dropped 1.37% in 2024.
• A 5-year view of Receivables - Net shows it stood at $8.1 billion in 2022, then rose by 1.31% to $8.2 billion in 2023, then declined by 0.36% to $8.2 billion in 2024, then gained by 8.66% to $8.9 billion in 2025, then climbed by 6.19% to $9.5 billion in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $9.5 billion in Q2 2026, $9.2 billion in Q1 2026, and $8.9 billion in Q4 2025.